Establishment of a WHO Reference Reagent for anti-Mullerian hormone

Jackie Ferguson¹, Jason Hockley², Peter Rigsby² and Chris Burns¹*¹

Abstract

Background: There is a need for a reference material to support the development and ensure the quality of immunoassays for human AMH. A batch of ampoules, coded 16/190, containing lyophilised recombinant AMH was evaluated in a WHO Collaborative Study. The aims of the study were to determine the AMH content in terms of the calibration of each immunoassay method, to predict long-term stability and to assess the suitability of the preparation to calibrate AMH immunoassays.

Methods: Study participants were asked to report the AMH content of specific dilutions of coded ampoules of 16/190 and a comparator preparation containing approximately half the AMH content. In each assay, participants also reported the AMH content of 22 patient samples to assess commutability. A robust all-laboratory geometric mean of the content estimates was determined using the laboratory geometric mean estimates. Commutability was assessed using a difference in bias approach. Stability was predicted by the measurement of thermally accelerated degradation samples.

Results: Seven laboratories performed twenty-one immunoassay method-platform combinations, sixteen of which provided data which met the validity criteria, giving a consensus geometric mean estimate of AMH content of 511 ng/ampoule (95% CI, 426–612, n = 16, GCV 42%) and a robust geometric mean of 489 ng/ampoule. By contrast, the GCV% for the all-laboratory geometric mean of the relative content estimates for the comparator sample to 16/190 was 12%. Commutability was assessed using 20 of the 22 representative patient samples. Of the valid assays, 16/190 was within the limits of acceptable commutability for 6 methods, partially commutable for a further 3 methods and non-commutable when measured by 7 methods. The preparation was predicted to be highly stable when stored at – 20 °C.

Conclusion: The majority of methods met the validity criteria. Content estimates showed a high between-method variability, yet assays exhibited a similar proportionality of response as demonstrated using the comparator sample. 16/190 was commutable in some but not all methods. On the basis of these results, it was agreed by the WHO Expert Committee on Biological Standardization to establish 16/190 as a WHO Reference Reagent for AMH with a content defined by consensus immunoassay of 489 ng/ampoule.

Keywords: Anti-Mullerian hormone, Assay, Immunoassay, International standard, Reference material, WHO
Background

In 2014, the WHO Expert Committee on Standardization (ECBS) approved the project to develop an International Standard for Mullerian Inhibiting Substance, also known as Anti-Mullerian Hormone (AMH) for immunoassay [1]. This was in response to repeated requests [2–4] from manufacturers and the clinical community who recognised both that there was an increase in the use of serum AMH measurement and also, that there was a discordance between the AMH measurements reported by the small number of immunoassays available at the time. As serum AMH concentration is considered a biomarker which represents the dynamic reserve of developing ovarian follicles, a major clinical use of AMH measurement is to assess female infertility and to gauge the likely response to ovarian stimulation procedures for assisted reproduction. Recently, there has been an increase in the number of manufacturers who offer, or who are in the process of developing, AMH immunoassays. This has led the WHO to approve the development of a WHO Reference Reagent for AMH (NIBSC code 16/190) with the aim of providing a reference preparation to further investigate the calibration and performance of assay methods.

Produced in ovarian granulosa cells, human AMH (NCBI RefSeq NP_000470.2) is a disulphide-linked homodimer comprising two subunits of 560 amino acids, thereby having a formula mass of 113 kDa for the dimer. Proteolytic cleavage of the homodimer forms N-terminal and C-terminal disulphide-linked dimers which remain non-covalently associated. To our knowledge, commercial immunoassays detect total AMH, either uncleaved, or cleaved but with the N- and C-terminal dimers remaining associated. Each subunit is glycosylated and it is likely that this property of AMH, specifically the effect of glycosylation in retarding migration by non-reducing SDS-PAGE, which has resulted in the accepted convention of reporting AMH immunoreactivity for an alternative approach, presents challenges. Technically, the assignment of mass units despite the measurand being a complex biological molecule with undefined post-translational modifications. The origin of the “nanogram of AMH” is unclear and the methods by which mass values were assigned to the first CHO-derived recombinant AMH immunoassay standards have not been reported [8, 9]. The unclear traceability of the mass assignment of AMH from the original assays to current assays has been described extensively elsewhere [10, 11]. By necessity, the calibration of new assay methods has relied on the use of serum value transfer using panels of human samples to transfer the AMH measurement from an AMH immunoassay that is considered the current market leader or ‘gold standard’ to the calibrators of the new assay. It is not known whether this process, over more than 15 years of assay development, has led to a situation where the current AMH content of a stated “nanogram of AMH” is different from the original measurements that described a nanogram of recombinant AMH. In situations such as this, where there is no formally established metrological traceability, one possible solution is to define an arbitrary unit of AMH immunoreactivity such as a WHO International Unit (IU) which is defined by the content of the current International Standard (IS) as determined through a WHO collaborative study [12]. However, the maturity of AMH measurement and the historic confusion caused by the discordant values reported by the first commercially available assays has led to the use of mass units being the accepted convention. If an IU of AMH immunoreactivity was established, there is a strong possibility that assay-specific conversion factors would be introduced to enable continued reporting of mass units.

However, foregoing the establishment of an IU of AMH immunoreactivity for an alternative approach, presents challenges. Technically, the assignment of mass units to a reference material requires the use of Système International (SI)-traceable physicochemical methods which precludes the use of measurement procedures with a biological component [13]. For proteins, assignment in SI units with unambiguous traceability has been successfully achieved only for small, unmodified proteins such as growth hormone (22 kDa) [14] and insulin (5.8 kDa) [15, 16]. Furthermore, once physicochemical reference methods have been developed to accurately measure AMH, for instance tryptic peptide isotope dilution mass spectrometry [17], there is still the question of which formula mass to use to convert the molar quantities reported by these methods to mass units.

The challenges highlighted above, outline the context in which we proceeded to formulate and manufacture the reference material coded NIBSC 16/190. Building on work previously undertaken to develop and assess a stable, lyophilised formulation of AMH, [11], the batch
of ampoules coded 16/190 comprised recombinant 
CHO-derived AMH, lyophilised from a formulation con-
taining trehalose and casein. Ampoules of 16/190 were 
then evaluated in a WHO international collaborative 
study, the results of which are summarised here. Full de-
tails of the results of the collaborative study are reported 
to the WHO ECBS as part of the process to establish a 
WHO reference material. This report, WHO/BS/ 
2019.2363, is available on-line [18].

Methods
Materials
CHO-derived, recombinant AMH purified from the cul-
ture media of stable cell line LR-MIS, was donated to 
NIBSC by Professor Patricia Donahoe (Director) and Dr. 
David Pépin of the Pediatric Surgical Research Labora-
tories, Massachusetts General Hospital, USA. In this cell 
line, the coding sequence for human AMH sequence has 
been modified at amino acids 423–428 from RAQR/S to 
RARR/S to improve cleavage at this position to produce 
the active form of the protein [19]. Bovine casein from 
herds certified as BSE free was obtained from Calbio-
chem (San Diego, USA). Trehalose was obtained from 
Sigma-Aldrich (Poole, UK).

Preparation of the candidate reference material
The content of the donated preparations of AMH was 
estimated using an AMH Gen II ELISA (Beckman-
Coulter, High Wycombe, UK) before adding at a 
nominal concentration of approximately 1 μg/ml to a 
2100 ml volume of formulation buffer containing 
0.24% (w/v) casein and 0.5% (w/v) trehalose. The bulk 
formulation was distributed into 3 mL siliconized glass 
ampoules at 0.5 mL per ampoule. After lyophilization 
and sealing under nitrogen according to procedures 
described by WHO [13], the batch, coded 16/190 was 
stored at –20°C.

Preparation of a comparator sample
To assist with the evaluation of the candidate prepar-
ation, a comparator sample containing approximately 
half the content of AMH as the candidate, 16/190, was 
prepared. For this, formulation containing approximately 
0.5 μg/ml AMH, 0.24% (w/v) casein and 0.5% (w/v) 
trehalose was filled at 0.5 mL per ampoule and lyophi-
lised as described above. In the collaborative study, the 
ampoules had been incubated at 4°, 20°, 37° and 45°C for 
21 months and 13 days.

Participants were asked to perform a minimum of 
two independent assays in which the AMH content of a 
dilution series of each coded sample was measured, in 
triplicate, alongside triplicate measurements of the 
AMH content of the serum and plasma samples. Where 
sample number was limited by the assay format, dupli-
cate measurements were performed. The (nominal) test 
centres of each coded sample were defined in the 
study protocol such that a reported, all-laboratory 
mean reflect the GM estimate for each concentration could be 
calculated. Thermal degradation samples were coded D-H 
and were treated in the same manner as the candidate 
materials.

Statistical analysis
Assessment of the immunoreactivity of the candidate 
standard, 16/190
Analyses were performed with AMH concentrations as 
reported by the participants, using results from samples 
A, B and C diluted to the nominal concentration range 
of 0.125–16 ng/ml only. To determine if a method 
showed acceptable dilutional linearity, linear regression 
analysis was applied to each sample in each assay run to 
estimate the slope of log_{10} reported concentration 
against log_{10} nominal concentration. The r^2 value was 
confirmed to exceed 0.975 in all cases. Methods were 
considered invalid if the geometric mean slope for any 
of samples A, B or C was outside the range [0.91, 1.10]. 
In addition, an individual assay run was only concluded 
to be acceptable if the ratio of the coded duplicates [A: 
C] was between 0.91 and 1.10.

Results from all valid methods were corrected for dilu-
tion factor and combined to generate unweighted 
geometric mean (GM) estimates for each laboratory and 
these laboratory means were used to calculate overall 
unweighted geometric mean estimates. Variability be-
tween laboratories has been expressed using geometric 
coefficients of variation (GCV = [s^{10^{s-1}}] \times 100% where s 
is the standard deviation of the log_{10} transformed esti-
mates). To mitigate the influence of possible outliers 
and anomalous results, Huber’s robust geometric mean 
was also calculated using the R package ‘WRS2’ [20].
Assessment of stability
The relative immunoreactivities of the accelerated thermal degradation samples were used to fit an Arrhenius equation relating degradation rate to absolute temperature assuming first-order decay [21], and hence predict the degradation rates when stored at a range of temperatures.

Assessment of commutability
Commutability was assessed using a difference in bias approach by which, for each laboratory, the bias between the reported values for the patient samples and the consensus all-laboratory value for these samples, was compared with the bias between the reported values for the dilutions of the candidate preparation and the all-laboratory consensus values for each dilution.

Data used for analysis. AMHPlasma18 and AMHPlasma22 were excluded from the analysis as the AMH content was below or above, respectively, the range of some assays (n = 9 for AMHPlasma18, n = 7 for AMHPlasma22). All reported results were log10 transformed for analysis in order to achieve approximately constant scatter over the range of concentrations used. A consensus value for each sample was calculated as Huber’s robust mean of laboratory means using the R package ‘WRS2’ [20]. Bias values were then calculated for all reported results as the difference between the reported value and the study consensus value for that sample.

Determination of commutability criteria. The standard deviation of the bias values for patient samples was calculated within each laboratory and a pooled value, $s_p$, was calculated across all laboratories. Commutability criteria representing the maximum acceptable difference in bias were then set as ±$2s_p$. Reference standards were to be concluded as commutable if the observed bias was within the commutability criteria. For this commutability assessment, the bias for patient samples has been assumed to be constant over the concentration range used.

Results
Preparation of the candidate standard, 16/190
Manufacture of the candidate standard, 16/190, met the quality control parameters required by WHO. A total of 3814 ampoules were produced. Check-weights measured during filling demonstrated a mean fill weight of 0.4999 g (CV 0.58%, n = 12). The mean residual moisture content as determined by coulometric Karl Fischer titration was 1.810% (CV 46.45%, n = 12), mean headspace oxygen was 0.21% (CV 52.37%, n = 12) and the mean dry weight was 0.0030 g (CV 5.78%, n = 5).

Assay validity
In total, data from 42 assay runs from 21 assays methods were submitted to the study. Of these, 19 were different method/platform combinations as shown in Table 2. In accordance with the WHO guidelines for reporting a WHO collaborative study [13], data sets are anonymized as Laboratory methods 1–21 which does not reflect the order of listing in Table 2. The runs of 5 methods (Laboratory methods 8, 10, 11, 17 and 18) were excluded as the slope of the fitted regression line of the log10 reported concentration against log10 nominal concentration was outside the range [0.91, 1.10]. Two runs (Laboratory method 15, run 2 and method 19, run 2) were excluded as the ratio of the candidate to the coded duplicate of the candidate (A:C) was outside the limits [0.91, 1.10].

Value assignment of 16/190 and comparator sample, B
With the exclusions above, 16 methods provided data which met the validity criteria. From these, a geometric mean estimate of the AMH content in 16/190 Sample A and the coded duplicate, Sample C, was determined (Table 3 and Fig. 1). Estimates for the AMH content ranged from 282 ng/ampoule to 1157 ng/ampoule with a geometric mean 511 ng/ampoule (95% CI, 426–612, n = 16, GCV 42%) and a robust geometric mean of 489 ng/ampoule. The median estimate was 485 ng/ampoule with an interquartile range of 462–533 ng/ampoule.
Similarly, geometric mean estimates of the AMH content of the comparator sample B were calculated. These were expressed, for each of the 16 valid laboratory methods, relative to the estimate by that method for 16/190. The overall geometric mean of the potency of B, relative to 16/190, was determined as 0.53 (95% CI, 0.50–0.56, GCV 12%, \( n = 16 \)). Estimates of the AMH content measured in individual runs can be found in report WHO/BS/2019.2363 [18].

**Stability of 16/190**

Estimates of the mean relative immunoreactivity of ampoules stored at elevated temperatures were determined from data provided by 5 laboratory methods. As no significant change in relative immunoreactivity was observed in ampoules incubated at elevated temperatures for 21 months and 13 days, 16/190 is likely to be highly stable when stored at −20 °C.

**Commutability of 16/190**

Alongside dilutions of the ampouled preparations, participants were asked to measure, in triplicate, the AMH content of a range of patient samples. These were coded AMHSerum1–3 which were paediatric male serum samples prediluted with a pooled menopausal serum, AMH-Serum4, 5, 17 and AMHPlasma21 and 22 from male donors and AMHSerum6–16 and AMHPlasma18–20 from female donors. Of these, 20 samples were included in the analysis of commutability with AMHPlasma18 and 22 being excluded as described above. If the AMH content was outside the range of an assay (laboratory method 1 and 13), participants chose to dilute the sample or to report it as out of range.

The commutability of the candidate standard was assessed at 6 nominal dilution of 0.5, 1, 2, 4, 8 and 16 ng/ml AMH. Where participants measured different dilutions (Laboratory methods 2 and 3, and method 12 in which the specified dilutions were prepared gravimetrically), interpolated values were used. The limits for acceptable bias difference were calculated from the standard deviation of the bias of the serum samples from all laboratories as described above. These were defined as ±0.051, or 0.892 to 1.121 on the untransformed scale, i.e. the bias for a reference standard must be demonstrated to be not less than 89.2% and not more than 112.1% of the bias observed for patient samples. As the mean patient sample bias will be different for each laboratory method, the lower and upper limits that define acceptable commutability will be different for each method. These values are shown in Table 4 which also includes the overall mean bias for the reference material dilutions for each valid method. As this approach requires bias to be constant across the range of AMH concentrations, the slopes of the bias values of the reference material dilutions and patient samples are also shown in Table 4. Individual values and plots of the bias of each

---

### Table 2 The immunoassay methods and platforms used by to evaluate the proposed reference material for AMH, 16/190

| Access2 AMH immunoassay | Beckman-Coulter (performed by two laboratories) |
|-------------------------|-----------------------------------------------|
| Advia Centaur XP AMH immunoassay | Siemens |
| Architect i2000sr | Tellgen Corporation |
| Auto Lumo A2000 plus AMH immunoassay | Autobio Diagnostics Co Ltd |
| Caris200 AMH immunoassay | Guangzhou Darui Biotechnology Co. Ltd. |
| CL1000 AMH immunoassay | Beijing Leadman Biochemistry Co., Ltd. |
| CLA200 AMH immunoassay | Taizhou Ze Cheng Biotechnology Co. |
| CL2000i AMH immunoassay | Shenzhen Mindray BioMedical Electronics Co Ltd. |
| Cobas e411 AMH immunoassay | Roche (performed by two laboratories) |
| Cobas e801 AMH immunoassay | Roche |
| Dxl AMH immunoassay | Beckman Coulter |
| Gen II AMH ELISA | Beckman Coulter |
| iFlash3000 | Shenzhen YHLO Biotech Co. Ltd. |
| Maglumi 4000 plus AMH immunoassay | SNIBE Co. Ltd. |
| MenoCheck picoAMH ELISA | Ansh Labs |
| Unicell-S AMH immunochromatography assay | Shenzhen YHLO Biotech Co. Ltd. |
| Union-CO718 AMH ELISA | Shenzhen YHLO Biotech Co. Ltd. |
| Vidas 30 AMH fluorescence immunoassay | bioMerieux |
| Vidas PC AMH fluorescence immunoassay | bioMerieux |

The results from each method were assigned a code number which does not reflect the order of listing here.
patient sample and reference material dilution for each of the 16 valid methods are included in report, WHO/BS/2019.2363 [18].

As shown in Table 4, the mean overall bias for the reference material dilutions was within the limits of acceptable commutability for laboratory methods 2, 4, 7, 14, 15, 16, 19, 20 and 21. Of these, in three methods (15, 20 and 21), 16/190 was not commutable in 2 or 3 of the test concentrations so could only be considered partially commutable in these methods. This may be due to experimental variation (laboratory method 15 which is the same as method 4), non-constant bias (laboratory method 20) and the freezing of test samples prior to measuring (laboratory method 21 which is the same as method 7).

The candidate standard was not commutable with patient samples when measured by laboratory methods 1, 3, 5, 6, 9, 12 and 13. Of these, laboratory methods 1 and 13 were the same method on different platforms. Laboratory method 5 was the same as method 4 (in which 16/190 was commutable) but on a different platform and although the mean bias for the reference material dilutions was the same by these methods, by method 5, the bias for the patient samples was more negative resulting in the bias for the reference material dilutions being outside the upper limit of acceptable bias. For method 13, the bias values for were non-constant and it may be that this approach is not applicable for this method. An increasingly negative trend in bias was observed for the higher concentrations of 16/190 when measured by method 9.

### Table 3

| Lab | Sample A | Sample C | GM(A,C) | Sample B | Ratio of B to GM(A,C) |
|-----|----------|----------|---------|----------|-----------------------|
| 1   | 337      | 335      | 336     | 150      | 0.45                  |
| 2   | 623      | 624      | 624     | 283      | 0.45                  |
| 3   | 1094     | 1074     | 1084    | 548      | 0.51                  |
| 4   | 523      | 542      | 533     | 293      | 0.55                  |
| 5   | 520      | 537      | 528     | 284      | 0.54                  |
| 6   | 1182     | 1133     | 1157    | 554      | 0.48                  |
| 7   | 484      | 456      | 470     | 252      | 0.54                  |
| 8   |          |          |         |          |                       |
| 9   | 546      | 553      | 549     | 298      | 0.54                  |
| 10  |          |          |         |          |                       |
| 11  |          |          |         |          |                       |
| 12  | 499      | 506      | 502     | 324      | 0.65                  |
| 13  | 277      | 288      | 282     | 141      | 0.50                  |
| 14  | 481      | 470      | 475     | 253      | 0.53                  |
| 15  | 453      | 471      | 462     | 268      | 0.58                  |
| 16  | 461      | 467      | 464     | 203      | 0.44                  |
| 17  |          |          |         |          |                       |
| 18  |          |          |         |          |                       |
| 19  | 379      | 381      | 380     | 210      | 0.55                  |
| 20  | 472      | 498      | 485     | 312      | 0.64                  |
| 21  | 410      | 432      | 421     | 228      | 0.54                  |
| Geometric Mean | 508 | 513 | 511 | 269 | 0.53 |
| 95% Confidence Limits | 417–619 | 430–612 | 426–612 | 221–328 | 0.50–0.56 |
| GCV | 45% | 41% | 42% | 45% | 12% |
| Robust Geometric Mean | 487 | 494 | 489 | 265 | 0.53 |

Ampoules A and C are coded duplicates of the proposed reference material, 16/190. Ampoule B is a comparator preparation containing approximately half the AMH content.

**Discussion**

In response to repeated calls for a WHO IS to calibrate AMH immunoassays, a batch of ampoules, coded 16/190, was prepared by NIBSC and a collaborative study organised to assign a value to the material and to evaluate its suitability. The study, reported here, has provided
the first assessment of a stable, lyophilised preparation of recombinant, CHO-derived AMH by multiple immunoassay methods. There are however, limits to the scope of such a study in that each laboratory method is performed only two to three times, rather than multiple times on different days using different instruments, reagent lots and operators as would be required to fully explore within-assay variation. Despite this, it is clear that there is a wide variation in the estimates of the AMH content of 16/190 with estimates ranging from 282 ng/ampoule to 1157 ng/ampoule, resulting in a geometric mean content estimate from valid assays of 511 ng/amp (95% CI: 426–612, n = 16, GCV 42%) and a robust geometric mean of 489 ng/amp.

**Table 4** Assessment of the commutability of 16/190 with representative patient samples

| Laboratory | Mean Patient Sample Bias | Lower Limit | Upper Limit | Mean 16/190 bias | 16/190 Slope | Patient Samples Slope |
|------------|--------------------------|-------------|-------------|------------------|--------------|------------------------|
| 1          | −0.029                   | −0.078      | 0.021       | −0.149           | 1.02         | 1.04                   |
| 2          | 0.137                    | 0.088       | 0.187       | 0.143            | 0.98         | 1.08                   |
| 3          | 0.045                    | −0.005      | 0.094       | 0.348            | 1.02         | 0.98                   |
| 4          | −0.014                   | −0.063      | 0.036       | 0.033            | 1.01         | 1.04                   |
| 5          | −0.044                   | −0.094      | 0.005       | 0.033            | 1.00         | 1.06                   |
| 6          | 0.109                    | 0.060       | 0.159       | 0.386            | 1.08         | 1.07                   |
| 7          | −0.025                   | −0.074      | 0.025       | −0.029           | 0.97         | 0.98                   |
| 9          | 0.121                    | 0.072       | 0.171       | 0.065            | 0.96         | 0.95                   |
| 12         | −0.064                   | −0.114      | −0.015      | 0.008            | 0.99         | 0.97                   |
| 13         | −0.041                   | −0.090      | 0.009       | −0.223           | 1.06         | 1.06                   |
| 14         | −0.009                   | −0.059      | 0.040       | −0.025           | 1.00         | 0.97                   |
| 15         | 0.023                    | −0.027      | 0.072       | −0.015           | 1.02         | 1.04                   |
| 16         | 0.007                    | −0.042      | 0.057       | −0.002           | 1.00         | 0.93                   |
| 19         | −0.078                   | −0.127      | −0.028      | −0.111           | 1.00         | 1.03                   |
| 20         | 0.042                    | −0.008      | 0.091       | −0.008           | 1.00         | 0.93                   |
| 21         | −0.017                   | −0.066      | 0.033       | −0.063           | 1.06         | 0.97                   |

This shows the mean patient bias for each valid laboratory method, the upper and lower limits of acceptable commutability (±2sP) for each method and the mean bias values for 16/190 obtained by that method. Values underlined indicate where the mean bias is outside the limits of acceptable bias for that method. As this assessment requires the bias to be constant across the range of AMH concentrations measured, the slope of the bias for 16/190 and the patient samples is also shown.
By contrast, measurements of the comparator sample B, containing half the content of AMH, when expressed relative to 16/190, varied with the much lower GCV of 12%. This suggests that the 16 valid laboratory methods exhibited a similar proportionality in their detection of recombinant AMH. As such, possible sources of the observed inter-assay variability in content estimates may be differences in antibody affinity, reaction parameters or assay calibration. Given the unclear traceability of the mass unit of AMH and given that widely discrepant estimates were previously shown to be provided by assays using the same monoclonal antibodies, F2B 12/H and F2B 7/A [11], it is possible that the observed variation is due to differences in assay calibration. It is understandable that, in the absence of a global standard, manufacturers aim to align their methods to currently-available immunoassays to ensure consistency in the measurement of patient samples. We are aware of one manufacturer (Ansh Laboratories) who has pursued SI-traceable value assignment of their calibrators [22]. Other assays have used serum value transfer in which the AMH content of a bank of patient samples, as measured by the current market leading assay, is applied to the signal of the new assay, and therefore to the new calibrators. This approach successfully engineers inter-assay agreement between serum measurements but has the potential to artificially assign a mass value to a set of calibrators. If the calibrator AMH and serum AMH are not recognized by the capture and detection antibodies in an equivalent manner, as may be the case, for example, when bovine AMH calibrators are used, the range of estimates observed in this study is not wholly unexpected.

As expected, this has an impact on the commutability of the candidate reference material. To assess commutability, data from the measurement of the AMH content of 20 patient samples were analysed by an approach similar to that recommended by the IFCC Working Group on Commutability [23]. Of the 16 immunoassay methods which met the validity criteria, 16/190 was within the limits of acceptable bias difference for 6 methods. For a further 3 methods, the mean difference in bias of the nominal dilutions tested, was within acceptable limits for only 3 or 4 of the 6 nominal concentrations assessed. This may be explained by experimental variation, non-constant bias or freeze-thaw of test dilutions. For 7 methods, 16/190 was not commutable. Of these, 2 were the same method on different platforms and 1 was the same method as a commutable method but on a different platform.

As discussed above, the practice of serum value transfer to assign AMH concentration values to assay calibrators of different sources may produce a wide range of responses when presented with a single source of reference standard AMH, in this case human, recombinant AMH. More subtle commutability deviations, particularly where a related platform-assay combination has shown 16/190 to be commutable, may be improved with increased familiarity with the material such as in reconstitution, dilution and examination of the storage conditions of sample dilutions. Lack of commutability in a reference material has often been attributed to the source, matrix and processing that is required to achieve long-term stability in a product that can be readily transported worldwide at reasonable cost to all. It is noted that the concentration of the matrix of 16/190 will be extensively reduced once diluted to the concentrations measured in current assay methods. With regard to the preparation of commutable reference materials, Braga and Panteghini [24] state that ‘the qualification of the measurement procedures about their selectivity should be done independently and in advance’. Thus, it needs to be considered if enough is known about current AMH immunoassays, such as the extent of equivalence of antibody binding to native and calibrator AMH, to consider assessment of commutability appropriate at the current time. Defining the relationship would however, require that validated procedures are available to measure the concentration of the immunoassay calibrators independently of the signal derived from serum value transfer. This will require further technological advances in peptide and glycan identification and quantification.

There is an increasing awareness of the importance of traceability in laboratory medicine such that a measurement result can be related to a reference material through a documented unbroken chain of calibrations [24, 25]. The chain is comprised of a hierarchy of calibrators and measurement procedures, commencing with the Primary Reference material which is defined and measured by a primary reference measurement procedure. It is essential that the reference materials provided at all parts of the traceability chain are commutable. For reference materials calibrated in mass units, the reference measurement procedure must use procedures which are traceable to the SI unit of mass. As mentioned previously, this is a challenge for complex analytes such as glycoprotein hormones which exist in multiple isoforms. For these, international conventional calibrators such as WHO International Standards, have been used successfully to harmonize methods.

The unclear origins of the nanogram of AMH and its subsequent transfer between assays by serum value transfer are clearly far removed from the above metrological ideals for traceability in laboratory medicine. Yet, as discussed previously, there are robust reasons to maintain the accepted units of AMH immuno-reactivity. In addition, approval of the Elecsys® AMH assay (Roche) as a companion diagnostic in which the reported AMH
Concentration is used in an algorithm to calculate the patient dose of Rekovelle®, a follitropin delta product (Ferring Pharmaceuticals) further reinforces the current conventions [26, 27]. Also, this development highlights the challenges of introducing a WHO International Standard, should this result in a requirement for an assay, used as a companion diagnostic, to be recalibrated.

While recognising the issues described above, there is a responsibility to support the current use of AMH immunoassays and to provide a reference preparation which can be used to further investigate assay calibration and the performance of methods.

Conclusion
This study demonstrated that the majority of AMH immunoassays available for clinical use, recognised recombinant human AMH when reconstituted from the stable, lyophilised form provided in ampoules of the candidate reference material coded 16/190. Estimates of AMH content in terms of individual assay calibration showed considerable variability which may reflect historical calibration exercises and current approaches used to assign values to method calibrators which may be native, recombinant or non-human AMH. However, valid assays exhibited a similar proportionality of response as demonstrated by the low variability of the ratio of content estimates of a comparator sample to the content estimate of 16/190. It was recognised by WHO ECBS that the commutability data of this study would not support the establishment of 16/190 as a WHO International Standard. To this end, the WHO ECBS approved the establishment of 16/190 as a WHO Reference Reagent for AMH, human, recombinant. The status of the material as a WHO Reference Reagent, rather than a “full” WHO International Standard, reflects the commutability considerations described above and the resulting intended use as a material to investigate assay performance. Until a physicochemical reference method is available, the AMH content of 16/190 will be defined as 489 ng/ampoule which is the robust geometric mean of the estimates from valid assays. The material is available from NIBSC (nibsc.org).

Abbreviations
AMH: Anti-Müllerian hormone; CHO: Chinese hamster ovary; ECBS: Expert Committee on Biological Standardization; IFCC: International Federation of Clinical Chemistry; IU: International Unit; NIBSC: National Institute for Biological Standards and Control; SI: Système International; WHO: World Health Organization.

Acknowledgements
We gratefully acknowledge Professor Patricia Donahoe (Director) and Dr. David Pépin of the Pediatric Surgical Research Laboratories, Massachusetts General Hospital for the donation of recombinant AMH, the participants in the collaborative study, the Standardization Science Group, Standards Processing Division and Biostatistics Group at NIBSC.

Authors’ contributions
JF and CB conceived the study. JF designed and implemented the study with guidance from JH, PR and CB and performed data curation. JH and PR carried out the analysis and interpretation of the data. Review of data was undertaken by all authors. JF prepared the manuscript and JH, PR and CB critically reviewed the manuscript. All authors approved the final manuscript version.

Funding
This work is funded by NIBSC.

Availability of data and materials
The datasets supporting the conclusions of this article can be found at [18].

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors provide their consent for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Biotherapeutics Division, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, UK. 2Biostatistics Group, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, UK.

Received: 30 March 2020 Accepted: 6 August 2020
Published online: 15 August 2020

References
1. WHO Expert Committee on standardization; sixty-fifth report. World health Organization, vol. 993; 2015. p. 48.
2. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod BioMed Online. 2011;23: 411–20.
3. Harlow SD, Gass M, Hall JE, LobO R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ, STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of stage reproductive aging. J Clin Endocrinol Metab. 2012;97: 1159–68.
4. Nelson SM, Illiordromiti S, Fleming R, Anderson R, McNOnnachie A. Messow CM reference range for the antimullerian hormone generation II assay: a population study of 10,984 women, with comparison to the established diagnostics systems laboratory nomogram. Fertil Steril. 2014;101:523–9.
5. Budzik GP, Powell SM, Kamagata S, Donahoe PK. Mullerian inhibiting substance fractionation by dye affinity chromatography. Cell. 1983;34: 307–14.
6. Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfà EG, Frey AZ, Gash DJ, Chow EP, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685–98.
7. Pankhurst MW, McMellon IS. Human blood contains both the uncleaved precursor of anti-Mullerian hormone and a complex of the NH2- and COOH-terminal peptides. Am J Physiol Endocrinol Metab. 2013;305E1241–7.
8. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, Lhomme C, Picard JY, Bidart JM, Rey R. Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 2000;85:540–4.
9. Groome NP, Cranfield M, Themmen APN, Savjani GV, Mehta K. Immunological assay and antibodies for anti-Mullerian hormone. US Patent. 2011;No.US7897350.
10. Devailluy D, Andersen CY, Balam A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20:370–85.
11. Ferguson JM, Pépin D, Duru C, Matejtschuk P, Donahoe PK, Burns CJ. Towards international standardization of immunoasays for Mullerian
inhibiting substance/anti-Mullerian hormone. Reprod BioMed Online. 2018;37:631–40.
12. Coxon CH, Longstaff C, Burns C. Applying the science of measurement to biology: why bother? PLoS Biol. 2019. https://doi.org/10.1371/journal.pbio.3000338.
13. WHO Expert Committee on Standardization; fifty-fifth report. World Health Organization, Geneva, Switzerland; 2006;92:Annex 2:75–130.
14. Bayol A, Bristow A, Cherton E, Girard M, Jongen P. Somatropin and its variants: structural characterization and methods of analysis. Pharmeuropa Bio. 2004;2004:35–45.
15. Moore M, Ferguson J, Riggsby P, Burns C. Proposed 1st International Standard for insulin, human. Geneva: World Health Organization; 2019. ECBS Report WHO/BS/2019.2366 available at https://www.who.int/biologicals/expert_committee/BS.2019.2366_insulin_FINAL.pdf. Accessed 15 Jan 2020.
16. Fisher BV, Smith D. HPLC as a replacement for the animal response assays for insulin. J Pharm Biomed Anal. 1986;4:377–87.
17. Whiting G, Ferguson J, Fang M, Pepin D, Donahoe P, Matejtschuk P, Burns C, Wheeler JX. Quantification of Mullerian inhibiting substance/anti-Mullerian hormone polypeptide by isotope dilution mass spectrometry. Anal Biochem. 2018;560:50–5.
18. Ferguson J, Hockley J, Matejtschuk P, Riggsby P, Burns C. WHO International Collaborative Study of the Proposed WHO IS for Mullerian Inhibiting Substance/Anti-Mullerian Hormone, human, recombinant. Geneva: World Health Organization; 2019. ECBS Report WHO/BS/2019.2363 available at https://www.who.int/biologicals/expert_committee/BS.2019.2363_Anti-Mullerian_Hormone_FINAL.pdf Accessed 15 Jan 2020.
19. Pepin D, Hoang M, Nicolau F, Hendren K, Benedict LA, Al-Moujahed A, Sosulski A, Marmalidou A, Vaivas D, Donahoe PK. An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian inhibiting substance. Technology. 2013;1:63–71.
20. Mair P, Schoenbrodt F, Wilcox R. Wilcox robust estimation and testing; 2017.
21. Kirkwood TB. Predicting the stability of biological standards and products. Biometrics. 1977;33:736–42.
22. Visser JAL, Laven JSE, McLuskey A, Louwers YV, Van Dorp W, Themmen APN, Kalra B, Patel AS, Kumar A. Development of a sensitive and human specific AMH Chemiluminescence assay for the quantitative measurement of AMH in serum, plasma and follicular fluid. ENDO 2013 (San Francisco, USA). https://endo.confex.com/endo/2013endo/webprogram/Paper8640.html Accessed 15 Jan 2020.
23. Nilsson G, Budd JR, Greenberg N, Delatour V, Rej R, Panteghini M, Ceriotti F, Schimmel H, Weykamp C, Keller T, Camara JE, Burns C, Vesper HW, Markenbach F, Miller WG, IFCC Working Group on Commutability. IFCC working group recommendations for assessing commutability part 2: using the difference in Bias between a reference material and clinical samples. Clin Chem. 2018;64:455–64.
24. Braga F, Panteghini M. Commutability of reference and control materials: an essential factor for assuring the quality of measurements in laboratory medicine. Clin Chem Lab Med. 2019;57:967–73.
25. Beastall GH, Brouwer N, Quiroga S, Myers GL, prepared on behalf of the joint Committee for Traceability in laboratory medicine. Traceability in laboratory medicine: a global driver for accurate results for patient care. Clin Chem Lab Med. 2017;55:1100–8.
26. Nyboe Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC, ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 non-inferiority trial. Fertil Steril. 2017;107:387–95.
27. Illidromist S, Salje R, Dewailly D, Fairburn C, Fanchin R, Fleming R, Li HWR, Lukaszuk K, Ng EHY, Pigny P, Tadros T, van Helden J, Weiskirchen R, Nelson SM. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod. 2017;32:1710–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.